Clinical Trial Update: Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial investigates the combination of azacitidine and enasidenib for IDH2-mutant myelodysplastic syndrome and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome with Excess Blasts

Drugs mentioned

• Azacitidine (Vidaza) (azacitidine)
• Enasidenib (Idhifa) (enasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 2 | Status: RECRUITING